Brief: Lumiradx Announces Commercial Shipment Of Its Point Of Care Nt-Probnp Test In Europe
31/01/2023 23:12
Jan 31 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX ANNOUNCES COMMERCIAL SHIPMENT OF ITS POINT OF
CARE
NT-PROBNP TEST IN EUROPE, SUPPORTING HEART HEALTH CHECKS IN UK
Source text for Eikon: ID:nGNE50fb1r
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing